Elevance Health, Inc. $ELV Shares Purchased by Nomura Asset Management Co. Ltd.

Nomura Asset Management Co. Ltd. boosted its stake in Elevance Health, Inc. (NYSE:ELV) by 2.3% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 85,171 shares of the company’s stock after buying an additional 1,898 shares during the period. Nomura Asset Management Co. Ltd.’s holdings in Elevance Health were worth $29,857,000 as of its most recent SEC filing.

Several other large investors have also recently added to or reduced their stakes in the stock. Vanguard Group Inc. increased its position in Elevance Health by 0.6% in the third quarter. Vanguard Group Inc. now owns 22,998,645 shares of the company’s stock worth $7,431,322,000 after buying an additional 141,747 shares during the period. Wellington Management Group LLP increased its position in Elevance Health by 4.8% in the third quarter. Wellington Management Group LLP now owns 6,621,297 shares of the company’s stock worth $2,139,473,000 after buying an additional 303,099 shares during the period. Artisan Partners Limited Partnership grew its stake in shares of Elevance Health by 24.5% in the third quarter. Artisan Partners Limited Partnership now owns 4,576,805 shares of the company’s stock worth $1,478,857,000 after purchasing an additional 901,626 shares in the last quarter. First Eagle Investment Management LLC grew its stake in shares of Elevance Health by 0.6% in the fourth quarter. First Eagle Investment Management LLC now owns 4,022,874 shares of the company’s stock worth $1,410,219,000 after purchasing an additional 24,271 shares in the last quarter. Finally, Norges Bank bought a new position in shares of Elevance Health in the fourth quarter worth $1,058,165,000. 89.24% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several research analysts have recently issued reports on ELV shares. Mizuho increased their price target on Elevance Health from $385.00 to $435.00 and gave the stock an “outperform” rating in a research note on Wednesday, May 20th. Jefferies Financial Group decreased their price target on Elevance Health from $395.00 to $391.00 and set a “buy” rating for the company in a research note on Monday, April 20th. The Goldman Sachs Group increased their price target on Elevance Health from $350.00 to $370.00 and gave the stock a “neutral” rating in a research note on Friday, April 24th. Robert W. Baird increased their price target on Elevance Health from $317.00 to $331.00 and gave the stock a “neutral” rating in a research note on Thursday, April 23rd. Finally, Sanford C. Bernstein increased their price target on Elevance Health from $384.00 to $424.00 and gave the stock an “outperform” rating in a research note on Friday, April 24th. Fourteen analysts have rated the stock with a Buy rating and nine have issued a Hold rating to the stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $407.05.

Elevance Health Trading Up 2.4%

Shares of ELV stock opened at $402.69 on Tuesday. The stock has a 50-day simple moving average of $345.97 and a 200 day simple moving average of $339.77. Elevance Health, Inc. has a fifty-two week low of $273.71 and a fifty-two week high of $408.00. The stock has a market capitalization of $87.45 billion, a P/E ratio of 17.13, a P/E/G ratio of 2.22 and a beta of 0.66. The company has a quick ratio of 1.48, a current ratio of 1.48 and a debt-to-equity ratio of 0.70.

Elevance Health (NYSE:ELV) last announced its earnings results on Wednesday, April 22nd. The company reported $12.58 earnings per share for the quarter, beating the consensus estimate of $10.74 by $1.84. Elevance Health had a return on equity of 15.58% and a net margin of 2.62%.The business had revenue of $49.49 billion during the quarter, compared to analysts’ expectations of $48.21 billion. During the same quarter last year, the business posted $11.97 earnings per share. The company’s quarterly revenue was up 1.5% on a year-over-year basis. Elevance Health has set its FY 2026 guidance at 19.850- EPS. On average, sell-side analysts expect that Elevance Health, Inc. will post 26.94 earnings per share for the current fiscal year.

Elevance Health Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Thursday, June 25th. Stockholders of record on Wednesday, June 10th will be issued a dividend of $1.72 per share. This represents a $6.88 annualized dividend and a dividend yield of 1.7%. The ex-dividend date of this dividend is Wednesday, June 10th. Elevance Health’s dividend payout ratio is currently 29.26%.

About Elevance Health

Elevance Health, Inc (NYSE: ELV) is a large U.S.-based health benefits company that provides a broad range of health insurance products and related services. Headquartered in Indianapolis, the company rebranded from Anthem, Inc to Elevance Health in 2022 while continuing to operate consumer-facing health plans under established state and national brands. Gail Boudreaux serves as chief executive officer and president, leading the company’s strategic focus on integrated health care and benefit delivery.

Elevance’s core activities include offering medical and specialty health plans for individuals, employers and government programs, including Medicare and Medicaid managed-care products.